3-year follow-up of TRANSFORM @ascocancer.bsky.social confirms significantly improved PFS with lisocel compared to SOC as second-line treatment for r/r LBCL (51% vs 26%): ascopubs.org/doi/10.1200/... PRO indicate improved HRQoL incl. Fatigue on treatment with lisocel, but similar long-term outcomes.

Fujimoto et al - Allo / auto in ENKT? Japanese data. • if in CR, ASCT appear superior to allo • if in PR, allo appears preferable • no impact on source of allo cells I normally allo these pts in CR1 so potentially practise changing. #18ICML #ICML25 #lymsm

Held et al - NIVEAU trial. Nivo-GemOx vs GemOx RR PTCL • 76 pts part of bigger trial • PFS no diff but was ⬆️ when MVA performed • responses ⬆️ • BUT ⬆️ toxic incl ‘infn’ (?hyperinfl state instead); ⬆️ deaths. Doubt there will be further development. #18ICML #ICML25 #lymsm

Patel: JNJ4496 (anti CD19/20 tandem CAR) RR DLBCL, 41BB costim • global Ph 1B • med age 72y • at RP2D, ORR 100%, CRR 80% • no G3+ CRS, 8% ICANs Very impressive results #18ICML #ICML25 #lymsm

Dreyfuss et al • ISRT & Pembro in localised relapsed cHL • RT dose varied according to response to Pembro • generally safe & good outcomes • did not seem to impair subseq Rx Consider for older relapsed pts #18ICML #ICML25 #lymsm

Dreyfuss et al • ISRT & Pembro in localised relapsed cHL • RT dose varied according to response to Pembro • generally safe & good outcomes • did not seem to impair subseq Rx Consider for older relapsed pts #18ICML #ICML25 #lymsm

Davison et al - PRO substudy of S1826 substudy. Interesting outputs: • NivoAVD showed more fatigued compared with BV-AVD on treatment but did not meet ‘clin significant’ threshold. • BV-AVD showed excess neuropathy which had a clinically meaningful impact. #ICML25 #lymsm

Evans et al: E-HIPI prognostic score early cHL • Holistic consortium • 1 binary factor: female sex better prog • 3 continuous: max tumour diam, Hb and albumin. Great work from Online calculator now available! #18ICML #ICML25 #lyms

Great work by @ABarrettHaem. NHSE data, older #Hodgkin pts. Outcomes ⬆️ with dox. Clearly may reflect selection, but interesting assocn seen between regional difference in dox use and outcome. Take home message: if safe to use dox then do use it! #18ICML #ICML25 #lymsm

Lewis et al - MRD analysis in ENRICH: IR vs R-chemo in 1L MCL • flow cytometry based • MRD- most rapid with BR • with RCHOP, even MRD- pts do poorly • with IR, no assocn with MRD & outcome #18ICML #ICML25 #lymsm

Flerlage et al • GLOW data nod LPHL • completely resected 1A, RT assoc with ⬆️ PFS compared with observation • unresected - ABVD-RT & RT do v well • no infield relapses if RT given Great work which significantly informs practice. #18ICML #ICML25 #lymsm

Rossi et al - baseline MTV, Dmax & esp combo, assoc with PFS. Independent effect of IPSS. Both factors improve prognostic impact of iPET. Based on AHL2011 study so all have 2x eacBEACOPDac as 1st 2 cycle. #18ICML #ICML25

Herrera et al - ctDNA in S1826 • 97% ctDNA + baseline • clearance at C3D1 assoc with PFS • within pos pts, those with minor ⬇️ assoc with esp poor outcomes • EOT ctDNA detection also assoc with poor outcomes CtDNA ripe for response adapted trials. #18ICML #ICML25 #lymsm

Ahmed et al - EBV & cHL subtype in S1826 study • EBV+ pts do much better with NAVD compared with BV-AVD (EBV- also do better but less marked) • non-NS histology also benefited more from NAVD. Biology is important! #lymsm #18ICML #ICML25

Things are hotting up for the first of 2 #Hodgkin lymphoma sessions today. #18ICML #ICML25 #lymsm

A no. of trials in RR DLBCL with RGemOx as comparator all show: • PFS med 2-3 mo • OS med 12-13 mo Well known tox of neutropenia, PN, fatigue, thrombocytopenia etc. Beaten by exptl arms in StarGlo, Polargo, Sunmo Take home: no more RGemOx pls - it’s defeated! #18ICML #lymsm

Feldman et al - acimtamig (CD16/CD30 engager) with alloNK in RR #Hodgkin • 24 pts, heavily preRx • ORR 88%, CRR 58% • 25% CRS with 1 G3, no ICANs or GvH Looks very active. Interested to see how it will developed further. #18ICML

Shah et al - Zamto-cel 3L+ DLBCL • tandem CD19 / CD20 41BB construct • non cryopreserved, short vein-vein • 69 pts • ORR 73%, CRR 51% • no G3+ CRS, 4% G3+ ICANS Clearly active but is it better than current agents? #18ICML

Sancho et al - POLARGO. • RGemOx vs Pola-RGemOx R/R DLBCL • 2L+ DLBCL (no ASCT eligible if 2L) • OS primary EP: signif adv 12.5mo vs 19.5mo • PFS & CMR rate better • tox modest - ⬆️ infn & PN • no effect of cell of origin Interesting but ? value if 1L PolaRCHP #18ICML

Stathis et al - feasibility of PET & ctDNA response adaptation in 1L DLBCL. • operationally deliverable with ctDNA turnaround median 9d • low rate PET+ and ctDNA+ at interim • assessing whether acala addition benefits those with Myd88 &/or CD79b mutns SAKK38/19 trial #ICML18

@dgermain21.bsky.social - fantastic work on LymphomaMAPs (microenv of DLBCL) looking at prognosis of CAR-T therapy. Showed that TEX archetype associated with signif worse outcome. Assoc with • exhausted T-cells • super-activated macrophages. #ICML18

Nivo-AVD vs BV-AVD in older pts (60+) with #Hodgkin. S1826 data. 99 eligible pts. 2y PFS • 89% Nivo-AVD • 64% BV-AVD 55% discontinued BV, 14% Nivo NRM 16% BV-AVD, 6% Nivo-AVD Transformational. If only we had access! #lymsm ascopubs.org/doi/10.1200/...

Pleased to work with my U.K. colleagues this analysis of PET data from our CHEMO-T study in PTCL led by #drgleeson and #drchua onlinelibrary.wiley.com/doi/10.1111/...

It’s the unboxing of the eighth edition of Hoffbrands Postgraduate Haematology. A real honour to be an editor alongside Adam Mead, Deborah Hay, Mike Lanffan and of course Victor Hoffbrand. Do get your copy!

Delighted to be sharing the stage with the great @broeckelmann.bsky.social at the 10th International Congress on Leukemia, Lymphoma and Myeloma. An erudite overview of the 1L setting - I’ve been given relapsed disease. #lymsm

Great to see this is in print!

Haynes et al - also data on bispecifics in secondary CNS lymphoma. 5/9 showed some response. #BSH2025 @bsochaem.bsky.social

Update on UK real world bispecific data. ITT ORR 41% & CRR 22.2%. G3+ infn 29%. PS, prior benda & refractory to last line assoc with worse outcome. Clear that some very ill and heavily pretreated pts being given bispecifics in real world setting. Should they be? #BSH2025 @bsochaem.bsky.social

ENRICH study - fantastic data from UK study. De David Lewis. IR superior PFS compared with 1L R-chemo with most benefit coming from RCHOP comparison. #BSH2025 @christianb.bsky.social

Great talk by Davis Lewis. Should we perform ASCT in any patient with mantle cell lymphoma? He argues no - irrespective of MRD data or use of BTKi 1L. Study by Fenske et was MRD driven but only 9% MRD- & the +ve pts did about the same as the -ve. #BSH2025 @bsochaem.bsky.social

At the #BSH2025 annual scientific meeting. Good chance to hear talks on things I don’t usually treat. Great talk in vWD. Most pts with low vWF don’t bleed, minority do & we don’t know why. Great talk by James O’Donnell @bsochaem.bsky.social

Great news - NICE have approved BV-AVD for 1L advanced stage Hodgkin. Great to have an additional option for patients. www.nice.org.uk/news/article...

Very proud of my team #drcamlewis and @allibarraclough.bsky.social for co-authoring this review out in @bloodjournal.bsky.social today. ashpublications.org/blood/articl...

Very happy to join our UK colleagues (e.g. @graham74gc.bsky.social) for the UK Hodgkin Lymphoma Forum 🇬🇧🥼🧑‍💻🇪🇺 Looking forward to lively discussions and to give a talk on how HL biology increasingly informs novel treatment approaches. Exciting times in HL research and care ✨

It was the Inaugural UK and Ireland Hodgkin Lymphoma Forum today. Incredible participation from all involved. Much thanks to Hartley-Taylor for organising and @broeckelmann.bsky.social and Daniel Molin as fantastic international colleagues. A real joy to be involved.

Great to see this published! Effect of replacing procarbazine for dacarbazine in escBEACOPP for Hodgkin treatment. Hugely beneficial effect on genotoxicity. Really no role for procarbazine in front line Hodgkin nowadays. #lymsm www.thelancet.com/journals/lan...

It’s the end of #ASH24. Enjoying some time in La Jolla with wonderful friends before heading back on the Heathrow red eye!

Neelapu: long term Zuma5 FU (Axi-cel FL) - 127 efficacy pts, R/R FL 2+ prior lines - at >5y FU, >50% alive, no further Rx - PFS at 5y approx 50% - NRM approx 15% - only 1 PD event after 4y - Apply to high risk incl POD24 Does support curative potential in FL #ASH24 #lymsm

Kim: ELM2, odronextamab in RR MZL - ORR 77% (all CRs) - CRS all G1/2 and no ICANS - durable responses on the whole - ongoing trial of Len-odron v R2 Great to see active drug being investigated specifically in MZL. #ASH24 #lymsm

Epco monotherapy in age >75 DLBCL #ASH24: - 45 pts, 38% age >85, all anthracycline ineligible - ORR 69%, CR 62% - 6-mo DOR 82%, PFS 73%, OS 81% - 5 fatal TEAEs (COVID, CMV, TLS), 8 pts d/c'd d/t TEAEs Seems fairly toxic; some debulking needed prior? #lymsm #gerionc

Salehi: genetic landscape of cHL - 2 sutypes H1 & H2 - neoantigen load linked to microenv traits - whole genome duplication assoc with poor prog - ctDNA interim or EOT+ strongly assoc with outcome #ASH24 #lymsm

Boegeholz - Biology of older cHL - >60y have lower mutationsl burden, more H2 - 15% have Bcl2-IgH translocation, poor prog - More likely EBV+ - subgroup with multiple viruses, ?immunosupp background - Risk score: Bcl2-IgH, EBV & high CtDNA Fantastic work! #ASH24 #lymsm

Serroukh - auto & allo in RR FL • large (>7000) EBMT dataset • ASCT assoc with durable PFS approx 30% (no of prior lines matters) • allo assoc with approx 50% durable PFS but 30% NRM, 17% 2y extensive GvH Great work! #ASH24 #lymsm

Van meerten - cohort 3 Zuma2 • Brexucel for BTK naive MCL • med prior 1 • very high ORR / CRR, 12mo DOR 80% but • 20% G3+ ICANs • 8% NRM Conclusions slide supports continued development in this setting. I would disagree. Safer options 2nd line for most. #ASH24 #lymsm

Jerkeman - acala+ritux in older MCL • MRD guided - 56% of low risk stopped due to MRD neg • safe, although 2 deaths due to aplastic anaemia (v odd?) • low risk had excellent outcomes (less so if p53, blastic / high Ki67) #ASH24 #lymsm

Le Gouill - OASIS II • IBR + R v I-Ven-R 1L MCL • DDPCR for MRD at 6mo • MRD- rate 82% with IVR, higher than any other regimen incl immunochemo • some excess AE: diarrhoea, neutrop, arrhyth IVR clearly a hugely active triplet #ASH24 #lymsm

Goldstein: factors predicting EOT MRD+ DLBCL - IPI did not associate with MRD+ at EOT - Stage, baseline ctDNA and interim assessments did associate - EOT MRD+ highly prognostic irrespective of IPI group #ASH24 #lymsm

Dubois: senior IPI - LYSA study developing prognostic score for 80y+ treated with immunochemo - years over 80, no. aaIPI score, albumin < 35, IPI > 3x ULN - clear impact in mean restrict survival time - outperforms existing prog scores. #ASH24 #lymsm

Wang: trends in CRS / ICANs in US - 3L use, 2017-19; 20-21; 22-23 eras - reduced CRS G3+ incidence & duration - reduced any grade ICANS - incr use of bridging and anakinra over time - no change cytop / infc #ASH24 #lymsm

Lee: 2nd line Axi-cel real world data - CIBMTR data, 444 pts - 52% would have been ineligible for Zuma7 - ORR, DoR, PFS & OS similar to Zuma7 - 12mo OS 'ineligible' gp seems lower than 'eligible' - CRS / ICANs as per trial Great to see RWE supporting approach. #ASH24 #lymsm